Colgate-Palmolive shares rise 5.07% premarket after Q4 results beat estimates, driven by strong sales and product launches.

Colgate-Palmolive surged 5.07% in premarket trading following strong Q4 results that exceeded earnings and revenue expectations. The company reported $0.95 EPS (vs. $0.91 expected) and $5.23 billion in revenue (vs. $5.12 billion expected), driven by resilient core operations and premium product growth. Analysts upgraded price targets, with Goldman Sachs and Piper Sandler raising estimates to $94–$96, while RBC Capital Markets maintained a positive outlook. Strategic initiatives, including a partnership with the WHO Foundation to enhance global oral health, and guidance for 2%-6% FY26 sales growth further fueled optimism. Despite a one-off $1.0 billion charge in FY2025 and mixed India results, the Q4 outperformance and bullish analyst sentiment directly aligned with the premarket rally.